EU Puts New Restrictions on the Use of Novartis’ Prexige

In the wake of Australia’s decision to pull Novartis’ COX-2 inhibitor Prexige from the market, healthcare regulators in Europe and elsewhere are imposing restrictions on the drug over fears that it may cause serious liver damage.
PharmaTimes